DE69612465D1 - Verwendung von Rifamyciderivaten zur Behandlung von Chlamydia-Infektionen - Google Patents

Verwendung von Rifamyciderivaten zur Behandlung von Chlamydia-Infektionen

Info

Publication number
DE69612465D1
DE69612465D1 DE69612465T DE69612465T DE69612465D1 DE 69612465 D1 DE69612465 D1 DE 69612465D1 DE 69612465 T DE69612465 T DE 69612465T DE 69612465 T DE69612465 T DE 69612465T DE 69612465 D1 DE69612465 D1 DE 69612465D1
Authority
DE
Germany
Prior art keywords
treatment
chlamydia infections
rifamycin derivatives
rifamycin
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69612465T
Other languages
English (en)
Other versions
DE69612465T2 (de
Inventor
Katsuji Yamashita
Kazunori Hosoe
Takayoshi Hidaka
George Todaro
Ribhi M Shawar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaneka Corp
Original Assignee
Kaneka Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaneka Corp filed Critical Kaneka Corp
Publication of DE69612465D1 publication Critical patent/DE69612465D1/de
Application granted granted Critical
Publication of DE69612465T2 publication Critical patent/DE69612465T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE69612465T 1995-12-08 1996-12-06 Verwendung von Rifamyciderivaten zur Behandlung von Chlamydia-Infektionen Expired - Lifetime DE69612465T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP32088295 1995-12-08
JP00263496A JP3963976B2 (ja) 1995-12-08 1996-01-10 クラミジア感染症治療剤

Publications (2)

Publication Number Publication Date
DE69612465D1 true DE69612465D1 (de) 2001-05-17
DE69612465T2 DE69612465T2 (de) 2001-08-23

Family

ID=26336071

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69612465T Expired - Lifetime DE69612465T2 (de) 1995-12-08 1996-12-06 Verwendung von Rifamyciderivaten zur Behandlung von Chlamydia-Infektionen

Country Status (6)

Country Link
US (1) US5786349A (de)
EP (1) EP0778022B1 (de)
JP (1) JP3963976B2 (de)
CA (1) CA2192255C (de)
DE (1) DE69612465T2 (de)
ES (1) ES2155566T3 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006328080A (ja) * 1995-12-08 2006-12-07 Kaneka Corp クラミジア感染症治療剤
US6316433B1 (en) 1998-12-18 2001-11-13 Kaneka Corporation Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
EP1511753A4 (de) * 2001-09-06 2005-10-12 Activbiotics Inc Antimikrobielle mittel und ihre verwendung
JP2005510534A (ja) * 2001-11-21 2005-04-21 アクティブバイオティクス インコーポレイティッド 標的化治療薬およびその使用
US7078399B2 (en) * 2001-12-13 2006-07-18 Activbiotics, Inc. Sulfhydryl rifamycins and uses thereof
US20040077533A1 (en) * 2002-05-23 2004-04-22 Sayada Chalom B. Methods and compositions for treating bacterial infections and diseases associated therewith
US20090149453A1 (en) * 2002-05-23 2009-06-11 Activbiotics Pharma Llc Methods and compositions for treating bacterial infections and diseases associated therewith
WO2003099217A2 (en) * 2002-05-23 2003-12-04 Activbiotics, Inc. Methods of treating bacterial infections and diseases associated therewith
TW200418485A (en) * 2002-09-23 2004-10-01 Activbiotics Inc Rifalazil compositions and therapeutic regimens
US20040126414A1 (en) * 2002-12-12 2004-07-01 Michaelis Arthur F. Methods and compositions for treating and preventing ear infections
CA2508823A1 (en) * 2002-12-12 2004-07-01 Activbiotics, Inc. Method and reagents for treating or preventing atherosclerosis and diseases associated therewith
JP2007503439A (ja) * 2003-08-22 2007-02-22 アクティブバイオティクス インコーポレイティッド リファマイシンアナログおよびそれらの使用法
US7820652B2 (en) * 2003-09-24 2010-10-26 Activbiotics Pharma, Llc Regimen for the administration of rifamycin-class antibiotics
CA2538078C (en) 2003-09-25 2012-12-04 Activbiotics, Inc. Rifalazil formulations
US7220738B2 (en) * 2003-12-10 2007-05-22 Activbiotics, Inc. Rifamycin analogs and uses thereof
CN1918172B (zh) * 2003-12-23 2011-09-14 活跃生物工艺学公司 利福霉素类似物及其用途
EP2056835A4 (de) * 2006-04-06 2013-01-30 Activbiotics Pharma Llc Pharmazeutische zusammensetzungen und ihre verwendungen
WO2007148713A1 (ja) * 2006-06-21 2007-12-27 Kaneka Corporation リファマイシン誘導体を有効成分とする血管性疾患処置剤または細胞増殖調節剤
WO2007148714A1 (ja) * 2006-06-21 2007-12-27 Kaneka Corporation リファマイシン誘導体を用いたインプラント
EP3004161B1 (de) 2013-05-31 2019-10-02 Genentech, Inc. Anti-zellwand-teichonsäureantikörper und konjugate
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
MA38686A1 (fr) 2013-05-31 2017-10-31 Genentech Inc Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés
US20170196917A1 (en) 2014-05-15 2017-07-13 Kabushiki Kaisha Yakult Honsha Agent for prevention and treatment of chlamydia infection
EP3226911A1 (de) 2014-12-03 2017-10-11 F.Hoffmann-La Roche Ag Antikörper gegen staphylococcus aureus mit rifamycinkonjugaten und verwendungen davon
EP3226908A1 (de) 2014-12-03 2017-10-11 F.Hoffmann-La Roche Ag Antikörper gegen staphylococcus aureus mit rifamycinkonjugaten und verwendungen davon

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690919A (en) * 1984-01-04 1987-09-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Benzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
JPS61128621A (ja) 1984-11-27 1986-06-16 Rohm Co Ltd フリツプフロツプ回路
JPS63183587A (ja) 1985-02-05 1988-07-28 Kanegafuchi Chem Ind Co Ltd ベンゾキサジノリフアマイシン誘導体
JP2544488B2 (ja) * 1988-11-01 1996-10-16 鐘淵化学工業株式会社 ３’―ヒドロキシベンゾキサジノリファマイシン誘導体
CA1304363C (en) * 1988-11-01 1992-06-30 Takehiko Yamane 3'-hydroxybenzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
JP2862912B2 (ja) * 1989-09-14 1999-03-03 鐘淵化学工業株式会社 ５’―（４―プロピルまたは４―イソプロピルピペラジニル）ベンゾキサジノリファマイシン誘導体

Also Published As

Publication number Publication date
CA2192255C (en) 2004-07-13
CA2192255A1 (en) 1997-06-09
ES2155566T3 (es) 2001-05-16
US5786349A (en) 1998-07-28
JP3963976B2 (ja) 2007-08-22
JPH09216824A (ja) 1997-08-19
EP0778022A1 (de) 1997-06-11
DE69612465T2 (de) 2001-08-23
EP0778022B1 (de) 2001-04-11

Similar Documents

Publication Publication Date Title
DE69612465T2 (de) Verwendung von Rifamyciderivaten zur Behandlung von Chlamydia-Infektionen
ATE235481T1 (de) Substituierte benzopyranderivate zur behandlung von entzündungen
NO974610L (no) Trisykliske forbindelser som er anvendbare for inhibering av G-proteinfunksjon og for behandling av proliferative sykdommer
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
ATE267180T1 (de) Phosphorderivate zur behandlung von aids
DE69635708D1 (de) Tetrandrin zur behandlung von augenentzündungen
DE59707519D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
DE69807466T2 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
ATE347372T1 (de) Vakzine zur behandlung von mycosen
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DE69834937D1 (de) Antibiotika zur behandlung von magengeschwuren
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
NO981822L (no) Anvendelse av proteinet GAX for behandling av cancer
FI980091A0 (fi) Menetelmä ylijäämäaktiivilietteen käsittelemiseksi
NO982582D0 (no) FremgangsmÕte for behandling av smerte
NO973366D0 (no) Fremgangsmåte for behandling av multippel sklerose
NO982562D0 (no) Sammensetning for behandling av smerte
DE69412178T2 (de) Apparat zur Behandlung von Lagen
BR9610382A (pt) Composição de tratamento do cableo
ATE235494T1 (de) Imino-aza-anthracyclonderivate zur behandlung von amyloidosis
DE69737088D1 (de) Therapeutisches agens zur behandlung von fiv infektionen
ATA93695A (de) Mittel zur behandlung von strahlenschäden
DE69819503D1 (de) Verwendung von 7-apha-methyl-17-alpha-ethynyl-estrane derivaten zur behandlung von atherosclerose
BR9507375A (pt) Tratamento de superficies particuladas
NO962812D0 (no) Fremgangsmåte for behandling av nervebetennelse

Legal Events

Date Code Title Description
8364 No opposition during term of opposition